Skip to main content

Knight Therapeutics Inc (GUD-T) Quote

Subscribe Register My account My account AdChoices
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 7.17
Day High 7.32
Open:7.28
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Latest
Inside the Market
Wednesday’s small-cap stocks to watch
Subscriber content
Inside the Market
Monday’s Insider Report: CFO and COO take profits in this peaking REIT yielding 5.9%
Subscriber content
Thinkstock
Inside the Market
Thursday’s small-cap stocks to watch
Subscriber content
Report on Business
Knight fight: Goodman fires back in escalating battle for Montreal pharmaceutical company
Subscriber content
Christinne Muschi For The Globe and Mail
Inside the Market
Thursday’s small-cap stocks to watch
Subscriber content
Inside the Market
Market movers: Stocks that saw action on Monday - and why
Subscriber content
Description
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

View Estimates zacks

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) Thomson Reuters

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) StockCalc

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) ValueEnfine

Latest Press Releases

More Stories
Leading Canadian Corporate Governance Expert Confirms Acute Board Conflicts and Governance Deficiencies at Knight Therapeutics
- CNW Group - Wed Apr 17, 6:00AM CDT
CNW Group - CMTX
Wed Apr 17, 6:00AM CDT
Report includes 54 recommended governance improvements for Knight and is available to all investors
Medison Issues Letter to Shareholders of Knight Therapeutics, Outlining Qualified, Independent Director Nominees and Common-Sense Plan to Build Value
- CNW Group - Tue Apr 16, 7:30AM CDT
CNW Group - CMTX
Tue Apr 16, 7:30AM CDT
Medison Biotech (1995) Ltd. ("Medison"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX: GUD) ("Knight" or the "Company"), today issued an open letter to Knight shareholders. Included below, the letter provides an overview of Medison's highly qualified, independent director nominees and its common-sense, low-risk plan to build long-term value for the Company and its shareholders.
Knight Therapeutics: Use of PROBUPHINE(TM) for Opioid Disorder Gains Momentum Across Canada; Subdermal Implant Now in Use from Coast to Coast
GlobeNewswire - Fri Apr 12, 4:00PM CDT
GlobeNewswire - CMTX
Fri Apr 12, 4:00PM CDT
Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a Canadian specialty pharmaceutical company, is pleased to announce that PROBUPHINE(TM), a new treatment in the fight against opioid addiction, is now being implanted in patients across the country.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 7.17 +0.28% increase
on 04/22/19
Period Open:7.46
Price movement based on the high, low and last over the given period.
7.53 -4.52% decrease
on 04/04/19
 -0.27 (-3.62%) decrease
since 03/22/19
3-Month 7.17 +0.28% increase
on 04/22/19
Period Open:8.13
Price movement based on the high, low and last over the given period.
8.25 -12.85% decrease
on 03/15/19
 -0.94 (-11.56%) decrease
since 01/22/19
52-Week 7.17 +0.28% increase
on 04/22/19
Period Open:7.79
Price movement based on the high, low and last over the given period.
8.81 -18.39% decrease
on 07/19/18
 -0.60 (-7.70%) decrease
since 04/20/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).